IVI Valencia
Valencia, 46015, Spain
NCT Number: NCT00633347
Oocyte donation is a well established procedure in assisted reproduction treatments (ART). It is demonstrated that the use of hormonal substitution therapy, for the synchronization of the cycles between the recipients and the donors, provides good results, similar to the ones obtained with the natural cycle. In the patients - recipients with preserved ovarian function, the recipient's natural cycle is annulled, thus preventing the spontaneous Luteinizing Hormone surge. Simultaneously and while waiting for the suitable donor, her endometrium is prepared. When the donation occurs and fertilization with the husband sperm takes place, her cycle is stimulated again in order to synchronize her window of implantation with the donor's ovulation.
Two different medications are commonly used to inhibit spontaneous ovulation: either GnRHa agonist or GnRH antagonists. The present study consists of the comparison between the single dose GnRH agonist (Decapeptyl 3,75 IM) and the 7 day dosage of GnRH antagonist (Cetrotide 0,25 mg). The administration of GnRHa is used fundamentally as a long liberation formulation, administered in a single intramuscular injection (IM), which is more practical in terms of use. Nevertheless, the unnecessary persistence and the potentially unfavorable action of GnRHa during the luteal phase and early gestation have questioned its use. The recovery of the Hypophysarian function begins only 8 weeks after the single injection of long liberation of triptorelina 3.75 mg. The GnRH antagonist (Cetrotide 0,25 mg) makes the hypofisary inhibition shorter than with the analogues and can prepare similar endometrium characteristics as a natural cycle. The recipients will be assigned randomly to a group of treatment or another.
Looking for future studies?
Notify Me18 year–44 year
Female
Interventional
Phase 4
Valencia, 46015, Spain
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Cetrotide 0.25 mg. daily/ 7 days
Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose
Time frame: 1 month
Time frame: 1 month
Instituto Valenciano de Infertilidad, IVI VALENCIA
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06659692
Genital Diseases, Infertility
Toronto, Ontario, Canada
View Trial DetailsNCT06924437
Abnormal Uterine Bleeding (AUB), Endometrial Polyp
Sohag, Egypt
View Trial DetailsNCT01511588
Adolescents, Amenorrhea
Bethesda, Maryland, United States
View Trial DetailsNCT07399535
Adnexal Diseases, Cysts
Karachi, Sindh, Pakistan
View Trial Details